These markers directly guide FDA-approved targeted therapies, including selpercatinib for RET-specific disease and dabrafenib plus trametinib for BRAF V600E-mutated anaplastic thyroid cancer. This evidence concerns the gene RET and thyroid gland undifferentiated (anaplastic) carcinoma.